Monte Rosa Therapeutics, Inc. (GLUE) Tops Q3 EPS by 2c

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) reported Q3 EPS of ($0.70), $0.02 better than the analyst estimate of ($0.72).

For earnings history and earnings-related data on Monte Rosa Therapeutics, Inc. (GLUE) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• BofA maintains underperform ratings on six BDC stocks
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand